Clinical Trial Update: Lumateperone for the Prevention of Relapse in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lumateperone for relapse prevention in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Lumateperone (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED